LONDON – ImmuPharma plc has pulled out of a $500 million cash deal for Lupuzor, over concerns that the lupus treatment would be beached following the acquisition of its licensee Cephalon Inc., by Teva Pharmaceutical Industries Ltd., which was finalized Oct. 14.London-based ImmuPharma is now scouting for a new partner for the drug, which is ready for Phase III.